drugset / Trial / NCT02255409

Clinical Study to Evaluate Safety, Immunogenicity of Investigational Flu Vaccine Compared to an Approved Flu Vaccine (QIV) in Children Previously Vaccinated in Trial V118_05

NCT02255409

Phase 3 Completed 607 enrolled Seqirus
RandomizedParallel-groupSingle-blindPrevention

Summary

Safety, Immunogenicity of an Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine Compared to Non-Adjuvanted Comparator Influenza Vaccine in Children Previously Vaccinated in Trial V118\_05

Timeline

Start
2014-10
Primary completion
2016-01
Completion
2016-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine Vaccine 0.25 ml
Subject Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine Vaccine 0.5 ml
Comparator non-adjuvanted Quadrivalent Influenza Vaccine Vaccine 0.25 ml
Comparator non-adjuvanted Quadrivalent Influenza Vaccine Vaccine 0.5 ml

Indications